Besides ibrutinib, people with M-CLL, devoid of TP53 aberrations and fit sufficient to tolerate FCR therapy, should still be excellent candidates for that latter, Together with the advantage becoming that this procedure is usually accomplished in 6 months though ibrutinib needs to be taken indefinitely. This feature will be specifically valuable fo